Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Basal Cell Nevus Syndrome 1

Interventions

Dacarbazine 27Nivolumab 26pembrolizumab 22Ipilimumab 203-ingenyl angelate 11Interferon-alpha 10Imiquimod 10Temozolomide 9trametinib 8Vemurafenib 8Photochemotherapy 8Aminolevulinic Acid 8methyl 5-aminolevulinate 7dabrafenib 7cemiplimab 7aldesleukin 7Introns 7Surgical Procedures, Operative 6Radiotherapy 6Interferon alpha-2 6Fluorouracil 6Paclitaxel 5Melphalan 5Interleukin-2 5Cisplatin 5Chemotherapy, Adjuvant 5talimogene laherparepvec 4binimetinib 4Specimen Handling 4Opdualag 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × IPI-926 × Dermatologic × Clear all
NCT06050122 2025-10-14

Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome

Sol-Gel Technologies, Ltd.

Phase 3 Active not recruiting
140 enrolled
Dermatologic

Basal Cell Nevus Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡